REPL — Replimune Income Statement
0.000.00%
Last trade - 00:00- $753.91m
- $342.01m
- 30
- 24
- 58
- 31
Annual income statement for Replimune, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 80.9 | 118 | 177 | 235 | 262 |
| Operating Profit | -80.9 | -118 | -177 | -235 | -262 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -80.9 | -118 | -174 | -215 | -247 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -80.9 | -118 | -174 | -216 | -247 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -80.9 | -118 | -174 | -216 | -247 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -80.9 | -118 | -174 | -216 | -247 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.73 | -2.26 | -2.99 | -3.24 | -3.07 |